What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Psychiatry
Julian Grosskreutz focuses on Neuroscience, Amyotrophic lateral sclerosis, White matter, Internal medicine and Neuroimaging.
The various areas that Julian Grosskreutz examines in his Neuroscience study include Calcium, Calcium signaling and Neurodegeneration.
The Amyotrophic lateral sclerosis study combines topics in areas such as Motor neuron, Locus and Genetic architecture.
His work deals with themes such as Frontal lobe, Diffusion MRI and Atrophy, which intersect with White matter.
His Internal medicine research focuses on Gastroenterology and how it relates to Symptom onset, Disease, Diagnostic accuracy and Heavy chain.
His Neuroimaging study integrates concerns from other disciplines, such as Postcentral gyrus, Dorsolateral prefrontal cortex, Pathology, Grey matter and Biomarker.
His most cited work include:
- Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis (289 citations)
- The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons (230 citations)
- Calcium dysregulation in amyotrophic lateral sclerosis (214 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Amyotrophic lateral sclerosis, Internal medicine, Neuroscience, Disease and Pathology.
His Amyotrophic lateral sclerosis research includes themes of White matter, Disease progression, Clinical trial, Physical medicine and rehabilitation and Neuroimaging.
His Internal medicine research incorporates themes from Gastroenterology, Placebo, Endocrinology and Cardiology.
His Neuroscience research is multidisciplinary, incorporating elements of Magnetic resonance imaging, Diffusion MRI, Calcium and Depolarization.
His research integrates issues of Oncology, Cohort and Rating scale in his study of Disease.
His studies deal with areas such as Biomarker, Voxel-based morphometry and Brainstem as well as Pathology.
He most often published in these fields:
- Amyotrophic lateral sclerosis (51.16%)
- Internal medicine (27.33%)
- Neuroscience (26.16%)
What were the highlights of his more recent work (between 2018-2021)?
- Amyotrophic lateral sclerosis (51.16%)
- Internal medicine (27.33%)
- Disease (22.67%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Amyotrophic lateral sclerosis, Internal medicine, Disease, Pathology and Disease progression.
In his works, Julian Grosskreutz conducts interdisciplinary research on Amyotrophic lateral sclerosis and Quality of life.
His Internal medicine research incorporates elements of Oncology and Rating scale.
His work carried out in the field of Disease brings together such families of science as Neurology, Bioinformatics and Intensive care medicine.
Julian Grosskreutz has researched Pathology in several fields, including Phenotype, White matter pathology and Voxel-based morphometry.
His work in White matter addresses issues such as Neuroimaging, which are connected to fields such as Fractional anisotropy and Voxel.
Between 2018 and 2021, his most popular works were:
- A proposal for new diagnostic criteria for ALS. (30 citations)
- Reaction to Endoplasmic Reticulum Stress via ATF6 in Amyotrophic Lateral Sclerosis Deteriorates With Aging. (24 citations)
- Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis. (22 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Disease
His main research concerns Internal medicine, Disease, Amyotrophic lateral sclerosis, Parkinson's disease and Clinical trial.
His work on Internal medicine deals in particular with Cohort, Observational study, Survival analysis, Hazard ratio and Riluzole.
The study incorporates disciplines such as Health related quality of life, Endoplasmic reticulum, Activating transcription factor and Neuropsychology in addition to Disease.
Julian Grosskreutz combines subjects such as Disease progression, Disease phases, Quality of life, Disease course and Progressive neurodegenerative disorder with his study of Amyotrophic lateral sclerosis.
His Parkinson's disease research integrates issues from Biomarker, Dementia, Depression and Intensive care medicine.
Julian Grosskreutz interconnects Spinal muscular atrophy, Intrathecal and Approved drug in the investigation of issues within Clinical trial.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
